CEU COURSE: IgG STRUCTURE AND FUNCTION EFFECT ON HEMOLYTIC DISEASE OF THE NEWBORN AND NEONATAL ALLOIMMUNE THROMBOCYTOPENIA SEVERITY

Hemolytic Disease of the Newborn (HDN) and Neonatal Alloimmune Thrombocytopenia (NAIT) pose significant morbidity and mortality risk.  Prevention and early detection are key.  Recent studies have described a correlation between immunoglobulin structure and clinical severity.  Typical IgG structure and immunoglobulin structural alterations along with the study results will be presented.


TARGET AUDIENCE / PREREQUISITES

Technologists, Technicians, Laboratory Managers. There are no participant prerequisites for this activity.

CEU CREDITS: 1.0 SUCCESS CEU Credit(s)TM

Enter Course


LEARNING OBJECTIVES
At the conclusion of this activity, participants should be able to:

  1. Recognize basic IgG structure and subclasses
  2. Discuss key aspects of how the following factors influence IgG functionality: a) IgG Subclass b) IgG Receptor structure c) Antibody glycosylation and fucosylation
  3. Describe findings of studies that evaluated IgG structure impact on NAIT and HDN severity 

LEARNING TASKS
To receive credit for this activity, participants must: 

  1. Review the presentation "IgG Structure and Function Effect on Hemolytic Disease of the Newborn and Neonatal Alloimune Thrombocytopenia Severity" or read the PowerPoint slides and accompanying notes available as a printable Adobe Reader® file.
  2. Take the online Post-Test.
  3. Complete the online Activity Evaluation.
  4. Print the certificate awarding 1.0 SUCCESS CEU credit(s)TM through the SUCCESSTM program.

FACULTY
Marla C. Troughton, M.D.
Medical Director
Alabama and Central Gulf Coast Region, Biomedical Services American Red Cross
Birmingham, AL

DISCLOSURES
Dr Troughton has indicated that she has no relevant financial relationships with commercial interests to disclose. No commercial support was received for this activity.

DISCLAIMER
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the American Red Cross Biomedical Services. Information herein is presented for educational purposes only and not to endorse off-label use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

DESIGNATION STATEMENT
The American Red Cross Biomedical Services designates this educational activity for a maximum of 1.0 SUCCESS1 CEU™; students should only claim credit commensurate with the extent of their participation in the activity.

DISCLOSURE STATEMENT
All faculty participating in ARCBS continuing education programs are expected to disclose to learners whether they do or do not have any real or apparent conflict(s) of interest or other relationships related to the content of their presentation(s); faculty are also expected to disclose off-label and/or investigational uses of products under discussion.

COURSE RELEASE DATE: 05/07/2018

EXPIRATION DATE: 05/06/2020

ESTIMATED TIME TO COMPLETE ACTIVITY: 1.0 hour(s)

Last modified: Friday, May 4, 2018, 01:38 PM